Loading…
Loading…
See exactly how OZEM's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for OZEM and 80,000+ other tickers.
Roundhill considers weight loss medications, particularly GLP-1 agonists, to be among the most groundbreaking innovations currently reshaping the global pharmaceutical landscape. This conviction underpins the Roundhill GLP-1 & Weight Loss ETF (OZEM), which is distinguished as the world's inaugural ETF exclusively focused on the GLP-1 and broader weight management sector. Notably, OZEM employs an active management approach.
Roundhill GLP-1 and Weight Loss ETF (NASDAQ: OZEM - Get Free Report)'s share price dropped 0.4% during trading on Tuesday. The company traded as low as $33.64 and last traded at $33.68. 17,650 shares traded hands during trading, a decline of 31% from the average daily volume of 25,480 shares. The stock had previously closed
Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.
With AI and space dominating many of the market's most popular investment themes, it can be difficult to find differentiated opportunities. Healthcare is often viewed as one of the more defensive sectors, supported by relatively steady demand regardless of the economic environment.
GLP-1 drugs are reshaping healthcare and consumer markets. These ETFs offer targeted exposure to the booming obesity-drug trend.
Eli Lilly and Novo Nordisk are accelerating global obesity pill launches as rising GLP-1 demand puts weight-loss ETFs in focus.